August 2016 IPO Market Review

by WilmerHale
Contact

The IPO market continued its tepid pace in August, with the month producing seven IPOs. Over the first eight months of 2016, the tally of 54 IPOs represents less than half the number of IPOs over the first eight months of 2015 and less than one-third the number of IPOs for the same period in 2014.

Gross proceeds in August were $932 million, bringing gross proceeds over the first eight months of 2016 to $9.66 billion, or 45% less than the $17.51 billion in gross proceeds over the first eight months of 2015.

IPOs by emerging growth companies (EGCs) have accounted for 81% of the year’s IPOs, down from 85% of the total number of IPOs in the period between enactment of the JOBS Act enactment in 2012 and the end of 2015.

Life sciences companies have accounted for half of the year’s new offerings, up from 47% in 2015 and 40% in 2014.

The median IPO offering size over the first eight months of 2016 was $90.5 million, just shy of the $91.7 million median for all IPOs in 2015. The median life sciences company IPO offering size in the first eight months of 2016 was $55.0 million, down 23% from the $71.8 million median in 2015, while the median non-life sciences company IPO offering size was $130.0 million, up 1% from the $128.5 million median for 2015.

The median annual revenue of IPO companies through the first eight months of 2016 was $60.6 million, or 60% above the $37.8 million median for 2015, but well below the $92.7 million median for the five-year period from 2010 to 2014.

Only a pair of companies that went public in August were profitable. Over the first eight months of 2016, 37% of IPO companies have been profitable, compared to 30% in 2015 and 36% in 2014—both figures well below the 54% that prevailed over the five-year period preceding 2014.

Over the first eight months of 2016, only two life sciences IPO companies were profitable. In contrast, two-thirds of non-life sciences IPO companies have been profitable in this period, compared to the 55% figure that prevailed over the five-year period that preceded 2016.

Year to date, the average IPO has produced a first-day gain of 9%, compared to average first‑day gains of 16% in 2015 and 14% in 2014, and representing the lowest such figure since 2002. The average life sciences IPO company over the first eight months of 2016 gained 5% in first-day trading, compared to 13% for all other IPO companies.

In the first eight months of 2016, 26% of IPOs have been “broken” (IPOs whose stock closes below the offering price on their first day), equal to the percentage of broken IPOs in 2015 and down slightly from the 27% figure for 2014.

At August month-end, the average IPO company was trading 32% above its offering price, 17% of companies were trading below their offering price and 24% were trading below their first-day closing price. Through August, the average 2016 life sciences IPO company was trading 13% above its offering price, while the average non-life sciences IPO company had almost quadrupled its first-day gain to end the month 51% above its offering price.

IPO activity in August consisted of offerings by the following companies listed in the order they came to market:

  • At Home Group, the leading home décor superstore based on the number of its locations and its large format stores, priced at the midpoint of the range and was flat in first-day trading.
  • First Hawaiian, a bank holding company headquartered in Honolulu, Hawaii and the state's largest full service bank as measured by assets, loans, deposits and net income, priced at the high end of the range and produced a first‑day gain of 5%.
  • Gemphire Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, priced below the range and ended its first day of trading down 8% from its offering price.
  • Atomera, a company engaged in the business of developing, commercializing and licensing proprietary processes and technologies for the $350+ billion semiconductor industry, priced at the expected price and gained 8% on its first trading day.
  • Medpace Holdings, one of the world’s leading clinical contract research organizations by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries, priced at the high end of the range and ended 21% above its offering price in first-day trading.
  • Protagonist Therapeutics, a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address significant unmet medical needs, priced an upsized IPO at the midpoint of the range and ended its first day of trading down 3% from its offering price.
  • Airgain, a leading provider of embedded antenna technologies used to enable high performance wireless networking across a broad range of home, enterprise, and industrial devices, priced below the range and was flat in first-day trading.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© WilmerHale | Attorney Advertising

Written by:

WilmerHale
Contact
more
less

WilmerHale on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.